Relationship Between Pentraxin 3 and Left Ventricular Diastolic Dysfunction in Patients With Obstructive Sleep Apnea: An Observational Study

Abstract

Abstract Purposes: The purpose of the study was to evaluate the expression and significance of plasma pentraxin 3 (PTX3) in patients with obstructive sleep apnea (OSA) with left ventricular diastolic dysfunction. METHODS: We enrolled 90 patients with OSA and 40 patients without OSA as the control group at the same time. We measured plasma PTX3 levels in all patients. All patients underwent polysomnography and transthoracic echocardiography was used to assess diastolic function in all patients. RESULTS: Among the 90 patients, 23 had mild OSA and 67 had moderate-to-severe OSA, pentraxin3 levels in the moderate-to-severe OSA group were significantly higher than those in the mild OSA and control groups, with median levels of 3.68, 2.19, and 2.00ng/ml, respectively (p < 0.05). The pentraxin3 levels gradually increased with the aggravation of left ventricular diastolic dysfunction(p < 0.05). The age, systolic blood pressure, AHI, and pentraxin3 were significantly associated with left ventricular diastolic dysfunction with ORs of 1.06 (95% CI = 1.01–1.11), 1.05 (95% CI = 1.00–1.08), 1.06(95% CI = 1.01–1.11), 2.08(95% CI = 1.18–3.66), respectively. CONCLUSIONS: Plasma PTX3 levels were significantly increased in OSA patients, and PTX3 was independently associated with left ventricular diastolic dysfunction in OSA patients.